8-K 1 auvi032221form8k.htm 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported) March 25, 2021

 

APPLIED UV, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-39480   84-4373308
(State or other jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification Number)

 

150 N. Macquesten Parkway

Mount Vernon, NY

  10550
(Address of registrant’s principal executive office)   (Zip code)

 

(914) 665-6100

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which
registered
Common Stock, par value $0.0001 per share   AUVI   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 1 

 

 

Item 4.02. Non-reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

 

On March 25, 2021, Adeptus Partners LLC, the independent registered public accounting firm for Applied UV, Inc. (the “Company”), informed the Audit Committee of the Board of Directors of the Company, that the Company’s consolidated audited financial statements for the fiscal year ended December 31, 2019 (the “2019 Financial Statements”) and the consolidated financial statements for the interim periods ended March 31, 2020, June 30, 2020 and September 30, 2020 (the “2020 Interim Financial Statements” and together with the 2019 Financial Statements, the “Affected Financial Statements” and the periods for which the Affected Financial Statements relate are collectively referred to herein as, the "Non-Reliance Periods") contained errors and should be restated. As a result, the consolidated financial statements and other financial information, investor presentations or other communications related thereto covering the Non-Reliance Periods should no longer be relied upon. The errors relate solely to the Company’s wholly-owned subsidiary, Munn Works, LLC and occurred prior to the Company’s initial public offering and at a time when neither the Company nor Munn Works, LLC employed any accounting staff.

 

In connection with the preparation of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the "2020 Form 10-K"), the Company’s management became aware that the Company’s consolidated financial statements for the Non-Reliance Periods contained errors related to revenue recognition as the Company had recorded a sale in the amount of $234,570 during December of 2019 which did not complete the earnings process and should have been deferred until the 2020 year in accordance with ASU 2014-09, Revenue from Contracts with Customers: Topic 606. As a result, the Company will restate its consolidated financial statements for the Non-Reliance Periods in the 2020 Form 10-K. The correction of the mis-recorded sale resulted in a 2.5% decrease of sales and a decrease of 8.4% of net income as set forth in the 2019 Financial Statements and a 8.0% increase of sales and a 73.5% decrease in net loss in the June 30, 2020 interim financial statements. 

 

The effects of the revenue recognition error on the Affected Financial Statements are shown in the tables below. 

 

   December 31, 2019  March 31, 2020 (Unaudited)
   As Reported  As Restated  As Reported  As Restated
Consolidated Balance Sheets:                    
Deferred revenue  $1,245,300   $1,479,870   $1,390,540   $1,681,876 
Total Current Liabilities  $2,767,960   $3,002,530   $2,836,706   $3,128,042 
Retained earnings (Deficit)  $1,384,289   $1,149,719   $1,362,678   $1,071,342 
Total Stockholders' Equity (Deficit)  $1,384,790   $1,150,220   $1,363,179   $1,071,843 

 

There were no changes to the Company’s consolidated balance sheets included in the Company’s restated June 30, 2020 and September 30, 2020 financial statements.

 

   Year Ended December 31, 2019
   As Reported  As Restated
Consolidated Statement of Operations:          
Net Sales  $9,329,720   $9,095,150 
           
Cost of Goods Sold   6,009,730    6,009,730 
           
Gross Profit   3,319,990    3,085,420 
           
Operating Expenses          
Research and development   —      —   
Stock based compensation   —      —   
Selling. General and Administrative Expenses   1,916,386    1,916,386 
Total Operating Expenses   1,916,386    1,916,386 
           
Operating (Loss) Income   1,403,604    1,169,034 
           
Other Income          
Gain on settlement   1,520,399    1,520,399 
Other Income   (15,736)   (15,736)
Total Other Income   1,504,663    1,504,663 
           
(Loss) Income Before Provision for Income Taxes   2,908,267    2,673,697 
           
Provision for Income Taxes   106,861    106,861 
           
Net (Loss) Income   2,801,406    2,566,836 
           
Basic and Diluted (Loss) Earnings Per Common Share  $0.56   $0.51 

 

   Three Months Ended March 31, 2020  Three Months Ended June 30, 2020
   As Reported  As Restated  As Reported  As Restated
Consolidated Statements of Operations:            
Net Sales  $1,528,400   $1,471,634   $1,404,028   $1,695,364 
                     
Cost of Goods Sold   1,161,813    1,161,813    1,180,769    1,180,769 
                     
Gross Profit   366,587    309,821    223,259    514,595 
                     
Operating Expenses                    
Research and development   —      —      —      —   
Stock based compensation   —      —      101,607    101,607 
Selling. General and Administrative Expenses   388,198    388,198    426,677    426,677 
Total Operating Expenses   388,198    388,198    528,284    528,284 
                     
Operating (Loss) Income   (21,611)   (78,377)   (305,025)   (13,689)
                     
Other Income                    
    —      —      —      —   
    —      —      7,497    7,497 
    —      —      7,497    7,497 
                     
(Loss) Income Before Provision for Income Taxes   (21,611)   (78,377)   (297,528)   (6,192)
                     
Provision for Income Taxes   —      —      —      —   
                     
Net (Loss) Income   (21,611)   (78,377)   (297,528)   (6,192)
                     
Basic and Diluted (Loss)  Earnings Per Common Share  $—     $(0.02)  $(0.06)  $—   

 

 

   Six Months Ended
June 30, 2020
  Nine Months Ended September 30, 2020
   As Reported  As Restated  As Reported  As Restated
Consolidated Statements of Operations:            
Net Sales  $2,932,428   $3,166,998   $4,493,061   $4,727,631 
                     
Cost of Goods Sold   2,342,582    2,342,582    3,825,037    3,825,037 
                     
Gross Profit   589,846    824,416    668,024    902,594 
                     
Operating Expenses                    
Research and development   —      —      65,037    65,037 
Stock based compensation   101,607    101,607    381,314    381,314 
Selling. General and Administrative Expenses   814,875    814,875    1,443,276    1,443,276 
Total Operating Expenses   916,482    916,482    1,889,627    1,889,627 
                     
Operating (Loss) Income   (326,636)   (92,066)   (1,221,603)   (987,033)
                     
Other Income                    
    7,497    7,497    11,905    11,905 
    7,497    7,497    11,905    11,905 
                     
(Loss) Income Before Provision for Income Taxes   (319,139)   (84,569)   (1,209,698)   (975,128)
                     
Provision for Income Taxes   —      —      —      —   
                     
Net (Loss) Income   (319,139)   (84,569)   (1,209,698)   (975,128)
                     
Basic and Diluted (Loss) Earnings Per Common Share  $(0.06)  $(0.02)  $(0.19)  $(0.18)

 

 

There were no changes to the Company’s consolidated statements of income included in the Company’s restated financial statements for the three-month period ended September 30, 2020.

 

The 2020 Form 10-K is expected to be filed with the U.S. Securities and Exchange Commission (the "SEC") on or before March 31, 2021. The Company has not filed and does not intend to file amendments to the Company’s Registration Statements on Form S-1 or its Quarterly Report on Form 10-Q for the periods affected by the restatement and correction of the Company’s consolidated financial statements as described above. Accordingly, investors and others should rely only on the financial information and other disclosures regarding the Non-Reliance Periods as disclosed in the 2020 Form 10-K, the Company’s two Registration Statements on Form S-1 described above, as amended by the post-effective amendments thereto and in future filings with the SEC (as applicable), and not rely on any previously filed registration statements or reports, investor presentations or other communications related thereto covering the Non-Reliance Periods.

 

The Company has concluded that the control deficiency that resulted in the failure to detect the accounting errors described above constituted a material weakness in internal control over financial reporting as of December 31, 2019. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company’s annual or interim financial statements will not be prevented or detected on a timely basis. The existence of one or more material weaknesses precludes a conclusion by management that a company’s disclosure controls and procedures and internal control over financial reporting are effective. The Company’s management has developed a remediation plan to address the material weakness and as of January 1, 2021 began using a new cloud based software which tracks the progress of jobs and more accurately reflects the percentage of job completeness ensure such revenue is recognized in the appropriate period.

 

The Audit Committee has discussed the matters disclosed in this Current Report on Form 8-K pursuant to this Item 4.02 with the Company’s  current independent registered public accounting firm, Adeptus Partners LLC.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number Description
16.1 Letter from Adeptus Partners LLC

 

 2 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  Applied UV, Inc.
     
Date: March 30, 2021 By: /s/ Keyoumars Saeed
  Name: Keyoumars Saeed
  Title: Chief Executive Officer

 

 

 3